| Product ID | 72626-2701_3176f9af-1cbb-4c22-a518-75ef434e218b | 
| NDC | 72626-2701 | 
| Product Type | Human Prescription Drug | 
| Proprietary Name | Sofosbuvir and Velpatasvir | 
| Generic Name | Velpatasvir And Sofosbuvir | 
| Dosage Form | Tablet, Film Coated | 
| Route of Administration | ORAL | 
| Marketing Start Date | 2018-11-14 | 
| Marketing Category | NDA AUTHORIZED GENERIC / NDA AUTHORIZED GENERIC | 
| Application Number | NDA208341 | 
| Labeler Name | Asegua Therapeutics LLC | 
| Substance Name | VELPATASVIR; SOFOSBUVIR | 
| Active Ingredient Strength | 100 mg/1; mg/1 | 
| Pharm Classes | Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Organic Anion Transporting Polypeptide 2B1 Inhibitors [MoA],Hepatitis C Virus NS5A Inhibitor [EPC],Breast Cancer Resistance Protein Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC],RNA Replicase Inhibitors [MoA],Nucleoside Analog [EXT] | 
| NDC Exclude Flag | N | 
| Listing Certified Through | 2021-12-31 |